Wesenhagen, Kirsten E. J.
Tijms, Betty M.
Boonkamp, Lynn
Hoede, Patty L.
Goossens, Julie
Dewit, Nele
Scheltens, Philip
Vanmechelen, Eugeen
Visser, Pieter Jelle
Teunissen, Charlotte E.
Funding for this research was provided by:
ZonMW Memorabel (733050824, 733050824, 733050824)
Article History
Received: 21 April 2022
Accepted: 22 June 2022
First Online: 15 July 2022
Declarations
:
: All procedures were approved by the medical ethics committee of the VU University Medical Center (VUmc), and written informed consent was obtained from all participants or surrogates.
: Not applicable.
: CT has functioned in advisory boards of Roche, received non-financial support in the form of research consumables from ADx Neurosciences and Euroimmun, performed contract research, or received grants from Probiodrug, Biogen, Eisai, Toyama, Janssen Prevention Center, Boehringer, Axon Neuroscience, EIP farma, PeopleBio, and Roche. PS has received consultancy fees (paid to the university) from AC Immune, Alzheon, Brainstorm Cell, ImmunoBrain Checkpoint, Novartis, and Novo Nordisk. Within his university affiliation, he is the PI of studies with AC Immune, FUJI-film/Toyama, IONIS, UCB, and Vivoryon. He is also an employee of Life Sciences Partners Amsterdam. EV is the co-founder of ADx NeuroSciences. JG and ND are employees at ADx Neurosciences. The other authors declare that they have no competing interests.